Pancreatic Cancer Research

ResearcherSichuan UniversityNo recent work listed

Li Mao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6058-5229; OpenAlex author ID A5100355203. Sources: OpenAlex.

Their work

Papers
17 (first author 5, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
32
Papers, trials and grants by year

2019: 4 papers · 2020: 5 papers · 2021: 5 papers · 2022: 2 papers · 2023: 1 paper

Papers 17

  1. Single-minded homolog 2 as a potential prognostic signature and assessment of its correlation with immune cell infiltration in pancreatic cancer. Co-author DOI 10.5114/pjp.2023.134317↗
  2. Prognostic value of systemic immune-inflammation index in patients with pancreatic cancer: a meta-analysis. Co-author DOI 10.1007/s10238-021-00785-x↗
  3. Adjusting CA19-9 values with clinical stage and bilirubin to better predict survival of resectable pancreatic cancer patients: 5-year-follow-up of a single cen… Co-author DOI 10.3389/fonc.2022.966256↗
  4. Clinical characteristics and treatment analysis of pancreatic acinar cell carcinoma: A single institutional comparison to pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.suronc.2021.101528↗
  5. EUS-CGN versus EUS-CPN in pancreatic cancer: A qualitative systematic review. Co-author DOI 10.1097/md.0000000000027103↗
  6. The germline/somatic DNA damage repair gene mutations modulate the therapeutic response in Chinese patients with advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12967-021-02972-6↗
  7. Long Non-Coding RNA MIR4435-2HG Promotes Glycolysis and Tumor Immunity in Pancreatic Cancer Through Absorption of microRNA-582-5p to Target GPX8 First author DOI 10.21203/rs.3.rs-1112369/v1↗
  8. Role of the microbiome in systemic therapy for pancreatic ductal adenocarcinoma (Review). First author DOI 10.3892/ijo.2021.5281↗
  9. Early recurrence detected by 18F-FDG PET/CT in patients with resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1097/md.0000000000019504↗
  10. Alteration of Transforming Growth Factor β Signaling Pathway Predicts Worse Prognosis in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000001522↗
  11. The Germline/somatic DNA Damage Repair Gene Mutations Modulate the Therapeutic Response in Chinese Patients With Advanced Pancreatic Ductal Adenocarcinoma Co-author DOI 10.21203/rs.3.rs-60530/v1↗
  12. Oral microbiome and pancreatic cancer. First author DOI 10.3748/wjg.v26.i48.7679↗
  13. miR-25 expression is upregulated in pancreatic ductal adenocarcinoma and promotes cell proliferation by targeting ABI2. Co-author DOI 10.3892/etm.2020.8595↗
  14. Assessment of preoperative hypercoagulability in patients with pancreatic ductal adenocarcinoma (PDAC) using rapid thromboelastography (r-TEG). First author DOI 10.1007/s11239-019-01908-8↗
  15. MiR-20a-5p regulates gemcitabine chemosensitivity by targeting RRM2 in pancreatic cancer cells and serves as a predictor for gemcitabine-based chemotherapy. Co-author DOI 10.1042/bsr20181374↗
  16. Downregulation of LINC01638 lncRNA inhibits migration and invasion of pancreatic ductal adenocarcinoma cells by reducing TGF‑β signaling. Co-author DOI 10.3892/mmr.2019.10699↗
  17. Linc-pint inhibits early stage pancreatic ductal adenocarcinoma growth through TGF-β pathway activation. Co-author DOI 10.3892/ol.2019.10111↗

Closest collaborators

The 25 strongest of 32 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Huimin Lü · 8 shared papers, 2019–2023 · strength 1.12
  2. Bole Tian · 6 shared papers, 2019–2022 · strength 0.79
  3. DuJiang Yang · 6 shared papers, 2019–2023 · strength 0.78
  4. Weiming Hu · 6 shared papers, 2019–2022 · strength 0.76
  5. Zuowei Wu · 3 shared papers, 2021–2023 · strength 0.51
  6. Xing Huang · 3 shared papers, 2021–2022 · strength 0.50
  7. Zihe Wang · 3 shared papers, 2021–2022 · strength 0.50
  8. Ang Li · 4 shared papers, 2020–2021 · strength 0.43
  9. Zhenlu Li · 3 shared papers, 2020–2022 · strength 0.43
  10. Chao Wu · 2 shared papers, 2021–2022 · strength 0.31
  11. Li Wang · 2 shared papers, 2020–2022 · strength 0.29
  12. Xubao Liu · 2 shared papers, 2020 · strength 0.23
  13. Yu Mou · 2 shared papers, 2019–2020 · strength 0.23
  14. Dan Cao · 2 shared papers, 2020–2021 · strength 0.23
  15. Lin Shui · 2 shared papers, 2020–2021 · strength 0.22
  16. Qian Hu · 1 shared paper, 2023 · strength 0.19
  17. Bole Tian · 1 shared paper, 2021 · strength 0.19
  18. Pengcheng Zhao · 1 shared paper, 2022 · strength 0.16
  19. Xing Huang · 1 shared paper, 2021 · strength 0.16
  20. Junjie Xiong · 1 shared paper, 2021 · strength 0.16
  21. Bole Tian · 1 shared paper, 2021 · strength 0.15
  22. Weiming Hu · 1 shared paper, 2021 · strength 0.14
  23. Shuangshuang Li · 1 shared paper, 2021 · strength 0.12
  24. Heli Gao · 1 shared paper, 2021 · strength 0.12
  25. Yi Cheng · 1 shared paper, 2021 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.